Acesso livre
Acesso livre

Hematologia

Linfo-histiocitose hemofagocítica secundária à COVID-19: uma série de casos.

19 Ago, 2021 | 12:19h

Haemophagocytic lymphohistiocytosis secondary to COVID-19: a case series – The Lancet Rheumatology

Diretriz | Abdome agudo em pacientes imunocomprometidos.

16 Ago, 2021 | 11:53h

Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines – World Journal of Emergency Surgery

Resposta de anticorpos à vacinação da COVID-19 em adultos com doença hematológica maligna.

13 Ago, 2021 | 12:17h

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease – JAMA Oncology

 

Comentário no Twitter

 

Características clínicas da trombocitopenia e da trombose imunes induzidas por vacina.

12 Ago, 2021 | 12:21h

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis – New England Journal of Medicine

Comentário: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD

Conteúdos relacionados:

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

 

Comentário no Twitter

 

Diretrizes de 2021 para tratamento de tromboembolismo na América Latina.

12 Ago, 2021 | 12:13h

ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America – Blood Advances

Revisão | Características clínicas e tratamento farmacológico da trombocitopenia trombótica com trombose de seio venoso cerebral desencadeada por vacina contra COVID-19.

11 Ago, 2021 | 10:53h

Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review – JAMA Cardiology

Conteúdos relacionados:

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

 

Comentário no Twitter

 

Diretriz | Endoscopia em pacientes em terapia antiplaquetária ou anticoagulante.

10 Ago, 2021 | 12:35h

Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update – Endoscopy

Diretriz | Detecção laboratorial e diagnóstico inicial das gamopatias monoclonais.

6 Ago, 2021 | 11:38h

Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology – Archives of Pathology & Laboratory Medicine

Estudo randomizado | Em pacientes não críticos hospitalizados com Covid-19, anticoagulação com heparina em dose terapêutica aumentou a probabilidade de sobrevivência à alta em comparação com a tromboprofilaxia usual.

5 Ago, 2021 | 12:02h

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 – New England Journal of Medicine

Editorial: Surviving Covid-19 with Heparin?

Comentários:

Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients – National Institutes of Health

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t – TCTMD

Canadian-Led International Study: Full-Dose Blood Thinners Benefit Moderately Ill COVID-19 Patients – University of Manitoba

 

Comentário no Twitter

 

Estudo randomizado | Em pacientes críticos hospitalizados com Covid-19, anticoagulação em dose terapêutica com heparina não resultou em melhores desfechos em comparação com a tromboprofilaxia farmacológica usual.

5 Ago, 2021 | 12:00h

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 – New England Journal of Medicine

Editorial: Surviving Covid-19 with Heparin?

Comentários:

Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients – National Institutes of Health

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t – TCTMD

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.